Electrophysiological and antiarrhythmic effects of a new class III antiarrhythmic drug nibentan in patients with paroxysmal supraventricular tachyarrhythmias

Kardiologiya

Volumn 36, Issue 6, 1996, Pages 38-51

  Maykov, E B ^a   Bakalov, S A ^a   Krutanov, I B ^a   Golitsin, S P ^a   Ruda, M Ya ^a   Rosenshtraukh, L V ^a   Chazov, E I ^a  

^a NONE

Author keywords

Class III antiarrhythmic drugs; Electrophysiological testing; Nibentan; Paroxysmal supraventricular tachycardias

Indexed keywords

EID: 1842395334     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-147.
2. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
3. Morganroth J., Goin J.E. Quinidine-related mortality in the shot-to medium-term treatment of ventricular arrhythmias: a meta-analysis. Circulation 1991;84:1977-1983.
4. Copen S.E., Antman E.M., Berlin J.A. et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990;82:1106-1116.
5. Falk R.H. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111:107-111.
6. Wang Y.S., Scheinman M.M., Chien W.W. et al. Patients with supraventricular tachycardia presenting with aborted sudden dearth; incidence, meshanism and long-term follow-up. J Am Coll Cardiol 1991;18:1711-1719.
7. Ranger S., Talajic M., Lemerey R. et al. Amplification of flecainide-induced ventricular conduction slowing by exercise. Circulation 1989;79:1000-1006.
8. Katritsis D., Camm A.J. Amiodarone in long-term prophylaxis. Drugs 1991;41:2:54-66.
9. Wichter T., Borggrefe M., Haverkamp W. et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease: results in patients with inducible and non-inducible ventricular tachycardia. Circulation 1992;86:29-37.
10. Edvardsson N. Comparison of class I and class III action in atrial fibrillation. Eur Heart J 1993;14:H:62-66.
11. Nademanee K., Feld G., Hendrickson J. et al. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72:555-564.
12. Singh B., Nademanee K. Sotalol: A beta-blocker with unique antiarrhythmic properties. Am Heart J 1987;114:121-139.
13. Camm A.J., Vince Paul. Sotalol for paroxysmal supraventricular tachycardias. Am J Cardiol 1990;65:67A-73A.
14. Klein R.S. and the ESVEM Investigators. Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the electrophysiology study versus electrocardiografic monitoring (ESVEM) Trial. Eur Heart J 1990;14:H:78-84.
15. Green H.L. for the CASCADE Investigators. The CASCADE Study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 1993;72:70F-74F.
16. Singh B.N. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J 1990;14:H:14-23.
17. Katritsis D., Camm A.J. New class III antiarrhythmic drugs. Eur Heart J. Ibid;93-99.
18. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J. Ibid;3-13.
19. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:2:686-690.